• 業務咨詢

  中國：

  Email: marketing@www.msjidi.com

  業務咨詢專線：400-780-8018

  （僅限服務咨詢，其他事宜請撥打川沙總部電話）

  川沙總部電話: +86 (21) 5859-1500

  海外：

  +1(781)535-1428(U.S.)

  0044 7790 816 954 (Europe)

  Email:marketing@medicilon.com

Targeted protein degradation (TPD) exemplified by PROTACs is an emerging strategy for next generation drug discovery. Threonine tyrosine kinase (TTK) is a dual-specific protein kinase that catalyzes phosphorylation of both serine/threonine and tyrosine residues. Researchers designed and synthesized TTK PROTACs, which demonstrated reasonable pharmacokinetic profiles. All the pharmacokinetic studies were carried out by Medicilon, according to the protocols and guidelines of the institutional care and use committee.

Reference:

Jibu Lu, et al. Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders. J Med Chem. 2022 Feb 10;65(3):2313-2328. doi: 10.1021/acs.jmedchem.1c01768.